Caribou Biosciences, Inc. Comprehensive Income
Caribou Biosciences, Inc. (CRBU) reported Comprehensive Income of -$24.33 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-13
- Caribou Biosciences, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$24.33M.
- Caribou Biosciences, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$25.21M.
- Caribou Biosciences, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was -$26.48M.
- Caribou Biosciences, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$27.50M.
- Caribou Biosciences, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$148.28M.
- Caribou Biosciences, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$148.88M.
- Caribou Biosciences, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$100.52M.
- Caribou Biosciences, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$100.80M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$24.33M 10-Q · filed 2026-08-13 | -$49.54M 10-Q · filed 2026-08-13 | -$76.02M derived: sum of 3 quarters · filed 2026-08-13 | -$103.51M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$25.21M 10-Q · filed 2026-05-07 | -$51.69M derived: sum of 2 quarters · filed 2026-05-07 | -$79.18M derived: sum of 3 quarters · filed 2026-05-07 | -$133.41M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$26.48M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$53.97M derived: sum of 2 quarters · filed 2026-03-05 | -$108.20M derived: sum of 3 quarters · filed 2026-08-13 | -$148.28M 10-K · filed 2026-03-05 |
| 2025-09-30 | -$27.50M 10-Q · filed 2025-11-12 | -$81.72M derived: sum of 2 quarters · filed 2026-08-13 | -$121.80M 10-Q · filed 2025-11-12 | -$157.82M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$54.23M 10-Q · filed 2026-08-13 | -$94.30M 10-Q · filed 2026-08-13 | -$130.33M derived: sum of 3 quarters · filed 2026-08-13 | -$163.90M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$40.08M 10-Q · filed 2026-05-07 | -$76.10M derived: sum of 2 quarters · filed 2026-05-07 | -$109.68M derived: sum of 3 quarters · filed 2026-05-07 | -$147.37M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$36.02M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$69.60M derived: sum of 2 quarters · filed 2026-03-05 | -$107.29M derived: sum of 3 quarters · filed 2026-03-05 | -$148.88M 10-K · filed 2026-03-05 |
| 2024-09-30 | -$33.58M 10-Q · filed 2025-11-12 | -$71.27M derived: sum of 2 quarters · filed 2025-11-12 | -$112.86M 10-Q · filed 2025-11-12 | -$146.35M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$37.69M 10-Q · filed 2025-08-12 | -$79.28M 10-Q · filed 2025-08-12 | -$112.77M derived: sum of 3 quarters · filed 2025-08-12 | -$122.62M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$41.59M 10-Q · filed 2025-05-08 | -$75.08M derived: sum of 2 quarters · filed 2025-05-08 | -$84.93M derived: sum of 3 quarters · filed 2025-05-08 | -$114.85M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | -$33.49M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | -$43.34M derived: sum of 2 quarters · filed 2025-03-10 | -$73.27M derived: sum of 3 quarters · filed 2025-03-10 | -$100.52M 10-K · filed 2025-03-10 |
| 2023-09-30 | -$9.85M 10-Q · filed 2024-11-06 | -$39.77M derived: sum of 2 quarters · filed 2024-11-06 | -$67.03M 10-Q · filed 2024-11-06 | -$93.50M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | -$29.93M 10-Q · filed 2024-08-06 | -$57.18M 10-Q · filed 2024-08-06 | -$83.65M derived: sum of 3 quarters · filed 2024-08-06 | -$110.75M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | -$27.26M 10-Q · filed 2024-05-07 | -$53.73M derived: sum of 2 quarters · filed 2024-05-07 | -$80.83M derived: sum of 3 quarters · filed 2024-05-07 | -$108.02M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | -$26.47M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | -$53.57M derived: sum of 2 quarters · filed 2024-03-11 | -$80.76M derived: sum of 3 quarters · filed 2024-03-11 | -$100.80M 10-K · filed 2024-03-11 |
| 2022-09-30 | -$27.10M 10-Q · filed 2023-11-07 | -$54.29M derived: sum of 2 quarters · filed 2023-11-07 | -$74.33M 10-Q · filed 2023-11-07 | -$92.95M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | -$27.19M 10-Q · filed 2023-08-08 | -$47.23M 10-Q · filed 2023-08-08 | -$65.84M derived: sum of 3 quarters · filed 2023-08-08 | |
| 2022-03-31 | -$20.04M 10-Q · filed 2023-05-09 | -$38.66M derived: sum of 2 quarters · filed 2023-05-09 | ||
| 2021-12-31 | -$18.61M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | -$67.06M 10-K · filed 2023-03-09 | ||
| 2021-09-30 | -$48.44M 10-Q · filed 2022-11-08 | |||
| 2021-06-30 | -$14.31M 10-Q · filed 2022-08-09 | -$27.47M derived: sum of 2 quarters · filed 2022-08-09 | ||
| 2021-03-31 | -$13.16M 10-Q · filed 2022-05-09 | |||
| 2020-12-31 | -$34.31M 10-K · filed 2022-03-21 | |||
| 2019-12-31 | -$23.43M 10-K · filed 2022-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |